Corporate Presentation - Delivering on our commitment to patients - Zealand pharma
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Contents Introduction: Zealand Today and 2025 Ambition Commercial Programs Clinical Programs Pre-Clinical Pipeline Additional Company Information Corporate Presentation 2
Forward looking statement This presentation contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, that provide Zealand Pharma’s expectations or forecasts of future events regarding the research, development and commercialization of pharmaceutical products. The reader is cautioned not to rely on these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward- looking statements to be incorrect, and which include, but are not limited to, the occurrence of adverse safety events; risks of unexpected costs or delays; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates or expansion of product labeling; failure to obtain regulatory approvals in other jurisdictions; product liability claims; and the direct and indirect impacts of the ongoing COVID-19 pandemic on our business, results of operations and financial condition. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. All such forward-looking statements speak only as of the date of this presentation and are based on information available to Zealand Pharma as of the date of this release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice. Corporate Presentation 3
Zealand Pharma is entering an exciting 2021 Plan for a successful launch of Zegalogue® and optimize commercialization Execute on our robust late-stage clinical pipeline Advance our early-stage programs into the clinic Maintain a strong financial and organizational position Corporate Presentation 5
We are boldly pursuing our ambition as a fully integrated biotech Invest in innovative peptide research platform 5x25 and robust pipeline Have 5 commercialized products by 2025 Optimize commercial operations Maintaining a strong balance sheet1 DKK thousand Fully operational US 1,500,000 infrastructure 1,000,000 High prescriber coverage Established relationships 500,000 with KOLs and HCPs 0 2016 2017 2018 2019 2020 Cash & cash equivalents Restricted cash Securities Corporate Presentation 1 6 Additional DKK 749 million gross proceeds secured through directed issue in January 2021
Significant pipeline evolution and a commitment to continue to deliver Preclinical Phase 1 Phase 2 Phase 3 Approved/ Cleared Metabolic V-Go® Wearable Insulin Delivery Type 2 Diabetes management ZEGALOGUE® (dasiglucagon) injection Severe hypoglycemia in diabetes Dasiglucagon S.C. Continuous Infusion Congenital hyperinsulinism Dasiglucagon Bi-Hormonal Artificial Pancreas Pump Type 1 Diabetes management Metabolic Dasiglucagon Adjustable Mini-Dose PBH/ T1D exercise-induced hypo BI 456906 GLP-1/GLU Dual Agonist1 Obesity/ NASH/ T2D ZP 8396 Amylin Analog Obesity ZP 6590 GIP Agonist Obesity Glepaglutide GLP-2 Analog Short Bowel Syndrome GI & Inflammatory Dapiglutide GLP-1/GLP-2 Dual Agonist SBS+ ZP 9830 Kv1.3 Ion Channel Blocker IBD+ ZP 10000 ɑ4β7 Integrin Inhibitor IBD Complement C3 Inhibitor2 Undisclosed 1 Licensed to Boehringer Ingelheim: EUR 345 million outstanding potential development, regulatory and commercial milestones + high single to low double digit % royalties on global sales 2 Licensed to Alexion: USD 610 million potential development, regulatory and commercial milestones + high single to low double digits % royalties on net sales Corporate Presentation 7
Severe hypoglycemia “Diabetes affects me all the time, Severe hypoglycemia is an acute, life-threatening condition resulting from a and I have to think about critical drop in blood glucose levels. Among it no matter what I do.” the most feared complications of diabetes Anders, living with Type 1 diabetes treatment, severe hypoglycemia requires another person for rescue Read more of Anders’ story at zealandpharma.com/anders-story Corporate Presentation 10
Severe hypoglycemia remains a major issue for people on insulin • Insulin treatment is the main cause of severe hypoglycemia in people with diabetes1 • 8.4M Adults and Children on Insulin Therapy2 • Approximately 4.0M patients are on Multiple Daily Injections of Insulin3 • Despite this, there were only approximately 540,000 patients with glucagon therapy in 20204 • Glucagon should be prescribed for all individuals at increased risk of level 2 or 3 hypoglycemia so that it is available should it be needed5 1The International Hypoglycemia Study Group. Lancet Diab and Endo 2019; 7,(5): 385-96.; 2 Diabetes Surveillance System, Centers for Disease Control: gis.cdc.gov/grasp/diabetes/diabetesatlas.html; Accessed March 1, 2021. 3 Brixner et al. ClinTher. 2019 Feb;41(2):303-313. 4 Symphony Health Trx Quantity; 5 ADA Standards of care. Diabetes Care 2021 Jan; 44 (Supplement 1): S1-S2 Corporate Presentation 11
ZEGALOGUE provides an attractive treatment option for patients and providers alike Recovery Consistent 99% of patients in the main adult phase 3 trial recovered within 15 minutes 10 minutes All pivotal phase 3 studies reported the same median time to recovery Median time to blood glucose recovery of 10 minutes in adults and children Corporate Presentation 12
ZEGALOGUE will launch at the right time in a growing market that is driven by innovation Launch timed to capture Rescue market growing with Innovation driven market with ‘Back to school’ seasonality new entrants new entrants capturing share TRx Units Dispensed (M) 1.2 +60% Rx Volume Lift +10% +6% Weekly Glucagon Market 0.9 ~300m USD 63% TRx Volume 78% 0.6 100% 1.0 0.9 0.9 0.3 37% 22% Jun Jul Aug Sep Oct 0.0 2018 2019 2020 2018 2019 2020 Source: Symphony Health TRx Quantity Legacy products New Entrants Corporate Presentation 13
V-Go® for optimized insulin delivery to Type 2 diabetes patients: clinically relevant reductions in A1c with less insulin 1. Cziraky M, et al. JHEOR 2019;6(2):70-83. 2. Grunberger G, et al. Drugs Real World Outcomes, 2019. 3. Lajara R, et al. Diabetes Therapy. 2015;6(4):531-545. 4. Harrison C, et al. Poster presented at AACE 26th Annual Scientific Meeting, May 2017. 5. Sutton D, et al. Advances in Therapy. 35(5), 631-643 2018. 6. Sink J, et al Poster Presented at Diabetes Technology Meeting, Nov. 2014. 7. Wu P, et al. Poster presented at AACE 27th Annual Scientific Meeting, May 2018. 8. Omer A, et al. Poster presented at ADA 73rd Scientific Sessions, June 2013. 9. Hundal R, et al. Poster presented at the Academy of Managed Care Pharmacy, April 2018. 10. Lajara R, et al. Endocr Pract 2016 Jun;22(6):726-35. 11. Mehta S, et al. Abstract published in The Journal of the American Osteopathic Association Nov 2017:117 and poster presented at OMED 12. Rosenfeld CR, et al. Endocr Pract. 2012;18(5):660-667. 14
Zealand is well positioned for delivering success Experienced Field Force Established Market Access Team § 15 years average diabetes experience § 20 years average experience with US payers § Long-standing presence with diabetes HCPs § Existing relationships with key national through V-Go and regional payers and PBMs through V-Go § Mix of live and inside sales resources covering § Expanded account management footprint across >80% of the Glucagon prescribing market commercial, medicaid, and medicare accounts Scalable Patient Services Footprint COVID Ready Promotional Mix § Existing V-Go® Patient Support capabilities & § Live and virtual customer engagement mix personnel across sales, marketing, market access, patient § Optimized patient support capability for support, and medical affairs ZEGALOGUE to help address patient and HCP § Tested and optimized to succeed in COVID and needs at launch post-COVID selling environment Corporate Presentation 15
Clinical programs• Corporate Presentation 16
Clinical project overview Congenital Post bariatric Obesity and Hyperinsulinism hypoglycemia associated metabolic diseases Type 1 diabetes Short bowel syndrome Corporate Presentation 17
Congenital Hyperinsulinism Congenital hyperinsulinism (CHI) is an ultra-rare and devastating congenital disorder in newborns. It is caused by a defect in pancreatic beta cells, resulting in insulin overproduction. This leads to persistently and dangerously low blood sugar levels (hypoglycemia). “Even though he appears to be such a normal kid, any moment his blood sugar can drop to a really dangerous level.” Read more of Crosby’s story at Julie, mom to Crosby who was born with zealandpharma.com/crosbys-story congenital hyperinsulinism Corporate Presentation 18
Congenital Hyperinsulinism (CHI) is an ultra-rare but devastating disorder in neonates and children A disease that affects 1:30,000 - 1:50,000 births • ~300 newborns are diagnosed every year with genetically determined CHI in the U.S. and EU1,2 Persistent episodes of hypoglycemia • Most common cause of serious episodes of hypoglycemia during childhood, due to inappropriate insulin secretion2,3 Substantial burden of disease • Insufficient response to existing medical treatment3 • High risk of seizures and permanent brain injury4 • Most severe cases require pancreatic surgery5 • Prolonged hospitalization and intolerable burden to patients, families, caregivers, and healthcare systems2,6 1 https://www.orpha.net/consor/cgi-bin/ (not including transient cases due to perinatal stress or diabetic mother); 2 Congenital Hyperinsulinism International. Available at: http://congenitalhi.org; 3 De Leon et al. Nat Clin Pract Endocrinol Metab 2007;3:57-68, Lubchenco and Bard. Pediatrics. 1971 May;47(5):831-8, Hussain et al. Diabetes 2005 54:2946–2951; 3 Thornton PS et al., J Pediatr. 2015;167(2):238-45; ); 4 Meissner T et al., Long-term follow-up of 114 patients with congenital hyperinsulinism. Eur J Endocrinol 2003;149:43-510; 5 Yorifuji et al. Pediatrics International 2014;56:467; 6 Eljamel et al. Orphanet Journal of Rare Diseases 2018;13:123 Corporate Presentation 19
Congenital hyperinsulinism Zealand has a comprehensive Phase 3 program to address the unmet need in CHI Trial 17109 – Completed* Trial 17103 - Ongoing Open-label extension study 17106 - Ongoing 12 patients, age 7 days-12 months. Maximum 44 patients, 32 patients, age 3 months-12 years. First patients enrolled; phase 3 trial age 1 month onwards Trial completed readout expected in 2021 Hypo-prone, maximum therapy, Newly diagnosed, dependent on IV Patients from 17109 and 17103 incl. pancreatic surgery glucose with ongoing positive benefit/risk 8 weeks of treatment 25 days of treatment Allows for long-term data (4 weeks follow-up) (4 weeks follow-up) *Dasiglucagon on top of standard of care (SOC) did not significantly reduce the rate of hypoglycemia compared to SOC alone when assessed by intermittent self-measured plasma glucose (primary endpoint). However, hypoglycemia was reduced by 40–50% when assessed by blinded continuous glucose monitoring (exploratory analysis). Dasiglucagon treatment was assessed to be safe and well tolerated in the study. 31 out of 32 patients have continued into the long-term extension study Corporate Presentation 20
Dasiglucagon in Type 1 Diabetes Management The Bihormonal Bionic Pancreas A person with type 1 diabetes depends on multiple daily insulin injections to maintain plasma glucose in the normal ranges. Read more at zealandpharma.com Corporate Presentation 21
Glycemic data from phase 2 study supports decision to move to phase 3 with bihormonal bionic pancreas Phase 2 home-use clinical trial testing Phase 3 trial initiation expected in H2 2021 based the iLet® bionic pancreas using Dasiglucagon1 on positive EoP2 meeting with the FDA Insulin-Only Bihormonal Mean CGM glucose level 149 mg/dL 139 mg/dL Time spent in range 71% 79% (70-180 mg/dL) Mean CGM glucose
The Bihormonal Bionic Pancreas Pivotal Trial (BH BPPT) will serve as the Phase 3 trial for use of Dasiglucagon in the iLet for adults and children with T1D Primary endpoint ADULTS (≥ 18y) Bihormonal with Dasiglucagon (BHBP) • A1C superiority of BH n ~ 350 Insulin-Only iLet (IOBP) BHBP iLet versus IO iLet (26w) Usual Care* Secondary endpoints • A1C superiority of BH iLet versus Usual Care BHBP • Non-inferiority for time in hypoglycemia/hypo PEDS (6–17y) Usual Care* events n ~ 350 Insulin-Only iLet (IOBP) BHBP • Long-term safety and Bihormonal with Dasiglucagon (BHBP) efficacy as measured over 52 weeks WEEKS 26 52 65 *Usual care will be the insulin treatment the patient is on when rendomized to the trial including multiple daily injections and any marketed insulin pump Corporate Presentation 23
Type 1 diabetes Commercial opportunity Potential glucagon market value of USD 1-3 billion in 2030 depending on bi-hormonal artificial pancreas pump share of the total diabetes pump market1 Pump adoption expected to Major growth drivers for dual increase rapidly hormone pumps Estimated number of pump users, U.S. only2 Fully-automated Bi-Hormonal AP pump Increasing number of insulin-treated Type 1 and 2 Diabetes Closed loop insulin-only AP pumps >1,000,000 patients3 Other traditional or hybrid insulin pumps Broader patient segment eligible for pump usage 400,000 Improving technology and pump system integration 2018 2025 2030 1Zealand projections based on glucagon WAC price of USD ~10-15/day. 2 Zealand forecast based on ZS Associates analysis, DataMonitor Diabetes Report 2018, ADA, LSI Report 2018, AACE Report 2014, Meddevicetracker, March 2017. Estimated pump users include T1D and T2D insulin-treated patients. Other traditional pump systems include suspend, predictive suspend, and hybrid closed loop pump systems. 3 JDRF. Corporate Presentation 24
Dasiglucagon adjustable minidose Zealand is exploring novel treatment opportunities for mini- doses of dasiglucagon Mini-doses of dasiglucagon increase blood glucose levels from hypoglycemia in people with type 1 Exercise-induced hypoglycemia in diabetes (T1D)1 T1D • In-clinic trials confirmed potential for dasiglucagon • “Free living” Phase 2 study planned for H1 2021 Post-Bariatric hypoglycemia (PBH) • In-clinic Phase 2 trial confirmed potential for dasiglucagon in treating PBH • Phase 2b outpatient study planned for H1 2021 1 Hovelmann et al. Diabetes, Obesity and Metabolism 2019; 21(3): 601-610 Corporate Presentation 25
BI 456906, a long-acting GLP-1-Glu dual agonist is in Phase 2 as a potential novel treatment of T2D, obesity and NASH Boehringer-Ingelheim is progressing the development of Zealand’s dual agonist BI 456906* Phase 1a: SAD trial COMPLETED Healthy Volunteers Phase 1b: MAD COMPLETED Obese/OW; 16 weeks Phase 1: PK/safety COMPLETED Japanese HV Expected completion Phase 2: T2D 350 subjects; 16 wks; Glycemic control, BW Q3 2021 Phase 2: Obesity Q3 2022 350 subjects; 46 weeks Phase 2: NASH Q1 2023 240 subjects; 48 weeks Sanchez-Garrido MA et al. Diabetologia 2017 * Licensed to Boehringer Ingelheim: EUR 345 million outstanding potential development, regulatory and commercial milestones + high single to low double digit % royalties on global sales 26
Short bowel syndrome ”My worst fear was to become Patients with SBS have undergone what I am today: a short bowel massive intestinal surgery resulting in significantly reduced or complete loss of patient.” intestinal function Marianne, living with short bowel syndrome Read more of Marianne’s story at zealandpharma.com/marianne-story Corporate Presentation 27
Glepaglutide is our lead candidate for treatment of SBS Glepaglutide1 – Phase 2 data with increases in intestinal absorption Long-acting stable GLP-2 analog following 3 weeks treatment • Forms depot at injection site with Change in wet weight Clear dose-response effective half-life of ~50 hours absorption (g/day)2 on multiple endpoints2 • Once- or twice-weekly dosing via a simple autoinjector • Increase in intestinal fluid and energy absorption • Reduction in fecal wet weight output • Increase in urine production • Increase in body weight • Appeared safe and well- tolerated Mean Baseline Wet Weight Absorption (g/day) 525 538 288 1 IP protection: Compound patent 2026 + 5 years patent term extension - Dosing regime (pending) 2038 - Clinical formulation (pending) 2039 2 Naimi, R., ASPEN 2018 Nutrition Science and Practice Conference (Abstract number 2829969t). Corporate Presentation 28
Glepaglutide – Pivotal Phase 3 trial progressing toward results in 2022 Trial design • Double-blind, placebo controlled trial in 129 SBS patients evaluating safety and efficacy of once and twice weekly dosing over 24 weeks Primary and key secondary endpoints • Reduction in weekly parenteral support (PS volume) • >20% reduction in PS volume • Reduction in weekly days on PS Corporate Presentation 29
Short bowel syndrome Commercial opportunity Opportunity to take majority share of future >USD 1.5 billion market with glepaglutide as potential best-in-class long acting GLP-2 analog Estimated number of treated SBS Major growth drivers for GLP-treatments patients and market value potential across major markets Increasing awareness of rehabilitation options5 The US 1, 2 EU 1, 3 Japan 4 Patients Value USD Patients Value USD Patients Value USD Improving GLP-2 treatment options 2020 1,000 ~0.4bn 2020 300 ~0.1bn 2020 0 - 2030 >4,000 >1.0bn 2030 >2,000 >0.4bn 2030 >1,000 TBD Improving therapy adherence RoW Potential to be determined 12020 patient and value estimate based on Takeda Q2 2020 financial report, Truven Redbook, WAC and 20-25% discount. 2 2025 forecast based on Transparency Market Research; Short Bowel Syndrome Market, 2017. Number of patients estimated by dividing with U.S. average price. 3 2030 forecast based on Zealand feasibility study 2018 and annual expected growth of 5%. Value based on existing GLP-2 WAC price. 4 No GLP-2 treatment currently approved in Japan. Patient forecast based on MHLW estimate. Price level to be defined by first GLP-2 introduction. 5 SBS prevalence doubled in one decade due to increased awareness and improved care (Brandt, 2016, Journal of Parenteral and Enteral Nutrition). Corporate Presentation 30
Dapiglutide has potential to treat SBS as well as a wider range of gastrointestinal diseases Dapiglutide1,2 - Long-acting GLP-1/GLP-2 Vehicle Clinical progress GLP-2 agonist dual agonist GLP1/GLP-2 dual agonist Phase 1a (SAD) Small intestine - Total surface2 area 1000 p
Pre-clinical pipeline• Corporate Presentation 32
Pre-clinical pipeline in obesity and other metabolic diseases are designed for dual pharmacology Zealand Pharma addresses dual Amylin analog and GIP agonist induce more weight loss in combination pharmacology from several angles with GLP-1 versus GLP-1 alone in preclinical obesity model Dual agonist (one molecule – two actions) ZP8396, amylin analog alone and in ZP6590, GIP agonist alone and in • BI456906 – GLP-1/Glucagon receptor-agonist combination with GLP-1 combination with GLP-1 Vehicle Vehicle Start of ZP Amylin GLP-1 analogue analogue treatment ZP Amylin analogue ZP GIP 700 4 GLP-1 GLP-1 analogue + ZP Amylin analogue 2 GLP-1 + ZP GIP 0 650 -2 Body weight (% change from day 0) -4 *** -6 6% Body weight (g) 600 -8 -10 Co-formulation or loose combo of mono -12 550 agonists -14 *** -16 17% • ZP8396 – Amylin analog 500 -18 -20 • ZP6590 – GIP receptor-agonist Pre-treatment GLP-1 analogue -22 *** 23% -24 450 -26 1 4 7 10 13 16 19 22 25 28 31 34 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 Time (Study days) Study days • ZP8396 allows for co-formulation with other • ZP6590 allows for co-formulation with other peptides, including GLP-1 and GIP peptides, including amylin and GLP-1 • Once weekly dosing • Predicted once weekly subcutaneous dosing • Phase 1 anticipated in 2021 • In IND enabling toxicology studies Corporate Presentation 33
Pre-clinical pipeline for on IBD and other chronic inflammatory diseases ZP9830, Kv1.3 blocker for T cell ZP10000, an α4β7 integrin inhibitor Complement C3 peptide inhibitor – driven chronic inflammatory for oral delivery outlicenced to Alexion diseases incl. IBD • Blockage of Kv1.3 ion channels on T effector memory • Binding kinetics on par with antibodies cells involved in auto-immunity and chronic • Potential for improved tissue penetration inflammation • Formulation for oral administration being optimized • Optimized for selectivity, potency and stability • In preparation for IND enabling toxicology studies 2000 250 200 • Novel long-acting peptide inhibitor of complement C3 IL-17A [pg/ml] 200 IFN-g [pg/ml] 1500 IL-2 [pg/ml] 150 150 • Attractive target for peptides not addressable by 1000 100 antibodies 100 500 50 50 • Lead molecule half-life extended with improved stability 0 0 0 in formulation and excellent binding properties to C3 -14 -12 -10 -8 -14 -12 -10 -8 -14 -12 -10 -8 Compound conc [log M] Compound conc [log M] Compound conc [log M] • USD 610 million potential development, regulatory and commercial milestones + high single to low double digits % royalties on net sales • Concentration-dependent inhibition of pro-inflammatory • Oral dosing of ZP10000 reduces colonic lesion & cytokine release (incl. IFN-g, IL-2 and IL17A) from inflammation in pre-clinical IBD disease model*** stimulated human whole blood* *Data on file. Concentration-dependent effect on pro-inflammatory cytokine release from Thapsigargin stimulated whole blood. **For lengths, cm; for Myeloperoxidase (MPO), units per gram protein. Inflammation score is a composite of observations and ranges from 0-4. Mean ± SEM ***ZP10000 administered QD at 100 mg/kg in lipid-based vehicle via oral gavage to mice. Corporate Presentation 34
Additional company information Corporate Presentation 35
Our next generation peptide platform builds on solid know-how and new innovative technologies Computational chemistry Library starting points Next generation peptide drugs Rational design Molecular display Formulation technologies 36
Strong balance sheet allows for continued investments Net Operating Expenses Cash position1 DKK 1,092.1 million / USD 166.9 million DKK 1.28 billion / USD 192.2 million DKK thousand DKK thousand 1,200,000 1,600,000 1,400,000 1,000,000 1,200,000 800,000 1,000,000 600,000 800,000 600,000 400,000 400,000 200,000 200,000 0 0 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 R&D expenses G&A expenses Sales & Marketing expenses Cash & cash equivalents Restricted cash Securities 1 Excludes an additional DKK 749 million gross proceeds secured through directed issue DKK/USD exchange rates used: December 31, 2020 = 6.54 and December 31, 2019 = 6.67 in January 2021 Corporate Presentation 37
Strategic Partnerships Strategic collaboration for GLP-1/glucagon Strategic collaboration for up to four dual agonist1 complement pathway targets3 • EUR 345 million outstanding potential development, regulatory • Novel long-acting peptide inhibitor of C3 identified and commercial milestones + high single to low double digit % • USD 610 million potential development, regulatory and royalties on global sales commercial milestones + high single to low double digits % • Product candidate for obesity/Type 2 diabetes/non-alcoholic royalties on net sales steatohepatitis (NASH) • Up to 3 Additional Targets: USD 15 million upfront/target • Once weekly dosing development/regulatory milestones similar to lead target, • Phase 2 initiated2 commercial milestones and royalties at slight reduction • Multiple opportunities for intervention points for novel targeted therapeutics 1Boehringer Ingelheim holds global development and commercial rights. 2 https://clinicaltrials.gov/ct2/show/NCT04153929. 3 Upfront payment of $25 million for the first target and $15 million equity investment at a subscription price of $18,68 per share. Corporate Presentation 38
Global organization Copenhagen, Denmark Boston, MA 329 Highly skilled employees and diverse teams1 Marlborough, MA New York, NY 1 As of December 31, 2020 Corporate Presentation 39
Zealand Pharma is facing an exciting 2021 Launch Zegalogue and optimize Advance our early pipeline commercialization Advance pre-clinical drug candidates towards Phase 1 initiation Execute launch readiness program for Zegalogue Initiate new pre-clinical projects Launch Zegalogue in late June 2021 Develop our next generation peptide platform Deliver on net revenue target for Zegalogue Deliver on net revenue target for V-GoTM Maintain a strong financial and organizational position Execute on clinical pipeline Secured a total of DKK gross 749.0 million through a direct issue and private placement of new shares –January 2021 Dasiglucagon for dual-hormone artificial pancreas pump: Initiate Phase 3 study Ensure disciplined financial management and productive investments Dasiglucagon for congenital hyperinsulinism: Deliver second phase III in 2021 and prepare NDA/MAA for execution in 2022 –ongoing Focus company on operational performance and organizational health Glepaglutide for short bowel syndrome: Continue patient enrolment in Phase 3 study – ongoing Dapiglutide for short bowel syndrome: Complete MAD Phase 1 program Corporate Presentation 40
Management Finance & Support Matt Dallas Chief Financial Officer US Business & Operations Emmanuel Dulac Frank Sanders Chief Executive Officer Research & Development Adam Steensberg Chief Medical Officer Technical Development & Operations Ivan M. Møller People & Organization Christina S. Bredal Business Development Marino Garcia Corporate Presentation 41
You can also read